drugset / Trial / NCT06577090
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
Timeline
- Start
- 2024-08-22
- Primary completion
- 2026-11-20
- Completion
- 2027-02-28
Outcome
Missed primary endpoint
release “In CBeyond TM, the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” skyebioscience.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimacimab | Monoclonal antibody | 200 mg | — |
| Subject | Nimacimab | Monoclonal antibody | 300 mg | — |
| Background | Semaglutide | Peptide | 2.4 mg | — |